CL2016000344A1 - Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas - Google Patents
Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidasInfo
- Publication number
- CL2016000344A1 CL2016000344A1 CL2016000344A CL2016000344A CL2016000344A1 CL 2016000344 A1 CL2016000344 A1 CL 2016000344A1 CL 2016000344 A CL2016000344 A CL 2016000344A CL 2016000344 A CL2016000344 A CL 2016000344A CL 2016000344 A1 CL2016000344 A1 CL 2016000344A1
- Authority
- CL
- Chile
- Prior art keywords
- fluoro
- preparation procedure
- pyrazolopyridines
- substituted
- morfolin
- Prior art date
Links
- LTYNYHHABUSSHS-UHFFFAOYSA-N 5-fluoro-1h-pyrazolo[4,3-b]pyridine Chemical class FC1=CC=C2NN=CC2=N1 LTYNYHHABUSSHS-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 abstract 2
- -1 AMINO Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/023—Preparation; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
<p>PROCEDIMIENTO DE PREPARACION DE 2-FLUORO-3-(AMINO, PIRROL-4-IL, PIPERAZIN-4-IL, PIPERIDIN-4-IL O MORFOLIN-4-IL)ACRIL ALDEHIDOS; COMPUESTO METANOSULFONATO DE 4-METIL-4-(2,2,3,3-TETRAFLUOROPROPIL)MORFOLIN-4-IO; Y COMPUESTO METANOSULFONATO DE 4-METIL-4-[2,3,3-TRIFLUOROPROP-1-EN-1-IL]MORFOLIN-4-IO.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190789 | 2011-11-25 | ||
| EP11192301 | 2011-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000344A1 true CL2016000344A1 (es) | 2017-02-10 |
Family
ID=47222101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001339A CL2014001339A1 (es) | 2011-11-25 | 2014-05-22 | Procedimiento de preparacion de un compuesto intermediario derivado de 5-fluoro-1h-pirazolopiridina; compuestos intermediarios que participan del mismo y formas cristalinas del compuesto final obtenido, el cual es util en el tratamiento de trastornos cardiocirculatorios. |
| CL2016000344A CL2016000344A1 (es) | 2011-11-25 | 2016-02-12 | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001339A CL2014001339A1 (es) | 2011-11-25 | 2014-05-22 | Procedimiento de preparacion de un compuesto intermediario derivado de 5-fluoro-1h-pirazolopiridina; compuestos intermediarios que participan del mismo y formas cristalinas del compuesto final obtenido, el cual es util en el tratamiento de trastornos cardiocirculatorios. |
Country Status (41)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| HUE053745T2 (hu) | 2011-11-25 | 2021-07-28 | Adverio Pharma Gmbh | Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában |
| CA2901636A1 (en) | 2013-02-21 | 2014-08-28 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
| TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| KR102615821B1 (ko) | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| TWI830835B (zh) * | 2018-12-17 | 2024-02-01 | 德商亞德維瑞醫藥有限公司 | 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物 |
| EP3914588A1 (en) * | 2019-01-22 | 2021-12-01 | Adverio Pharma GmbH | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine |
| WO2021156223A1 (en) | 2020-02-03 | 2021-08-12 | Adverio Pharma Gmbh | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| EP3925953A1 (en) | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| CN113336753A (zh) * | 2021-06-02 | 2021-09-03 | 中国人民解放军军事科学院军事医学研究院 | 一种利奥西呱的合成方法 |
| ES3068989T3 (en) * | 2021-08-31 | 2026-06-03 | Assia Chem Ind Ltd | Solid state forms of vericiguat and process for preparation thereof |
| ES2956054B2 (es) | 2022-05-03 | 2024-07-01 | Moehs Iberica Sl | 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT |
| CN115043835B (zh) * | 2022-06-17 | 2023-05-09 | 常州制药厂有限公司 | 一种维立西呱的精制纯化方法 |
| WO2024038398A1 (en) * | 2022-08-18 | 2024-02-22 | Torrent Pharmaceuticals Limited | Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses |
| WO2025114276A1 (en) | 2023-12-01 | 2025-06-05 | Krka, D.D., Novo Mesto | Solid oral composition comprising vericiguat |
| CN122421969A (zh) | 2023-12-20 | 2026-07-17 | 阿德弗里奥药品有限责任公司 | 维立西呱的给药方案 |
| CN117924280B (zh) * | 2024-03-20 | 2024-07-12 | 中国人民解放军军事科学院军事医学研究院 | 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途 |
| WO2026057833A1 (en) | 2024-09-16 | 2026-03-19 | Adverio Pharma Gmbh | Treatment of chronic heart failure with vericiguat |
| WO2026153905A1 (en) | 2025-01-17 | 2026-07-23 | Krka, D.D., Novo Mesto | Synthesis of vericiguat |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8606936D0 (en) * | 1986-03-20 | 1986-04-23 | Ici Plc | Organic compounds |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| ATE431347T1 (de) | 1996-10-14 | 2009-05-15 | Bayer Healthcare Ag | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen |
| US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| WO2000028822A2 (de) * | 1998-11-16 | 2000-05-25 | Basf Aktiengesellschaft | Herbizide 3-[benz(ox/thi)azol-7-yl]-1h-pyrimidin-2,4-dione |
| DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| AU2002221827A1 (en) | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
| DE10131987A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Pyridin-substituierte Pyrazolopyridinderivate |
| DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| CA2450961C (en) | 2001-06-22 | 2010-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006031175A1 (de) | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| JP5588339B2 (ja) | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化学化合物 |
| WO2009018415A1 (en) * | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| EP2262498A2 (en) | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| KR100979460B1 (ko) * | 2008-05-13 | 2010-09-02 | 한국과학기술연구원 | 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법 |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| UY33040A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
| DK3415515T3 (da) | 2009-11-27 | 2020-03-16 | Adverio Pharma Gmbh | Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat |
| UY33041A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040234A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| BR112014005110A2 (pt) | 2011-09-02 | 2017-04-18 | Bayer Ip Gmbh | pirimidinas aneladas substituídas e utilização das mesmas |
| HUE053745T2 (hu) * | 2011-11-25 | 2021-07-28 | Adverio Pharma Gmbh | Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában |
-
2012
- 2012-11-21 HU HUE18178621A patent/HUE053745T2/hu unknown
- 2012-11-21 EP EP15151593.9A patent/EP2896617B1/de active Active
- 2012-11-21 MY MYPI2018001784A patent/MY198086A/en unknown
- 2012-11-21 EA EA201892050A patent/EA201892050A1/ru unknown
- 2012-11-21 HR HRP20181818TT patent/HRP20181818T1/hr unknown
- 2012-11-21 UA UAA201703936A patent/UA120278C2/uk unknown
- 2012-11-21 EA EA201491028A patent/EA030018B1/ru not_active IP Right Cessation
- 2012-11-21 PE PE2018003205A patent/PE20190181A1/es unknown
- 2012-11-21 AU AU2012342547A patent/AU2012342547C1/en active Active
- 2012-11-21 ES ES18178621T patent/ES2864009T3/es active Active
- 2012-11-21 RS RS20181317A patent/RS57945B1/sr unknown
- 2012-11-21 DK DK18178621.1T patent/DK3421470T3/da active
- 2012-11-21 PL PL18178621T patent/PL3421470T3/pl unknown
- 2012-11-21 PE PE2018003204A patent/PE20190180A1/es unknown
- 2012-11-21 MY MYPI2014701335A patent/MY168412A/en unknown
- 2012-11-21 MY MYPI2018001783A patent/MY197904A/en unknown
- 2012-11-21 BR BR122020001312-5A patent/BR122020001312B1/pt active IP Right Grant
- 2012-11-21 PT PT12790891T patent/PT2782914T/pt unknown
- 2012-11-21 TR TR2018/16203T patent/TR201816203T4/tr unknown
- 2012-11-21 PL PL15151593T patent/PL2896617T3/pl unknown
- 2012-11-21 MX MX2017014201A patent/MX375872B/es unknown
- 2012-11-21 KR KR1020147017000A patent/KR101993022B1/ko active Active
- 2012-11-21 SG SG10201604192XA patent/SG10201604192XA/en unknown
- 2012-11-21 BR BR112014012414-0A patent/BR112014012414B1/pt active IP Right Grant
- 2012-11-21 UA UAA201703940A patent/UA119269C2/uk unknown
- 2012-11-21 PE PE2014000713A patent/PE20142359A1/es active IP Right Grant
- 2012-11-21 LT LTEP12790891.1T patent/LT2782914T/lt unknown
- 2012-11-21 AP AP2015008243A patent/AP3898A/en active
- 2012-11-21 DK DK12790891.1T patent/DK2782914T3/en active
- 2012-11-21 AP AP2014007705A patent/AP2014007705A0/xx unknown
- 2012-11-21 MX MX2014006018A patent/MX357481B/es active IP Right Grant
- 2012-11-21 ES ES15151593.9T patent/ES2603028T3/es active Active
- 2012-11-21 KR KR1020177033016A patent/KR101943788B1/ko active Active
- 2012-11-21 PL PL12790891T patent/PL2782914T3/pl unknown
- 2012-11-21 LT LTEP18178621.1T patent/LT3421470T/lt unknown
- 2012-11-21 EP EP18178621.1A patent/EP3421470B8/de active Active
- 2012-11-21 CN CN201611138520.4A patent/CN106905314A/zh active Pending
- 2012-11-21 SG SG10201604196VA patent/SG10201604196VA/en unknown
- 2012-11-21 SG SG11201402111QA patent/SG11201402111QA/en unknown
- 2012-11-21 EA EA201690521A patent/EA031602B1/ru not_active IP Right Cessation
- 2012-11-21 RS RS20161004A patent/RS55387B1/sr unknown
- 2012-11-21 CR CR20190057A patent/CR20190057A/es unknown
- 2012-11-21 HU HUE15151593A patent/HUE031029T2/en unknown
- 2012-11-21 EP EP12790891.1A patent/EP2782914B1/de active Active
- 2012-11-21 SI SI201231439T patent/SI2782914T1/sl unknown
- 2012-11-21 CU CUP2015000124A patent/CU24354B1/es unknown
- 2012-11-21 PT PT181786211T patent/PT3421470T/pt unknown
- 2012-11-21 DK DK15151593.9T patent/DK2896617T3/en active
- 2012-11-21 CN CN201610014399.8A patent/CN105503867B/zh active Active
- 2012-11-21 CN CN201280066381.2A patent/CN104159898B/zh active Active
- 2012-11-21 KR KR1020197003426A patent/KR102026059B1/ko active Active
- 2012-11-21 SI SI201230770A patent/SI2896617T1/sl unknown
- 2012-11-21 PT PT151515939T patent/PT2896617T/pt unknown
- 2012-11-21 WO PCT/EP2012/073276 patent/WO2013076168A1/de not_active Ceased
- 2012-11-21 UA UAA201406974A patent/UA116623C2/uk unknown
- 2012-11-21 EA EA201690520A patent/EA033455B1/ru not_active IP Right Cessation
- 2012-11-21 CA CA2856706A patent/CA2856706C/en active Active
- 2012-11-21 SI SI201231895T patent/SI3421470T1/sl unknown
- 2012-11-21 CA CA3040720A patent/CA3040720C/en active Active
- 2012-11-21 LT LTEP15151593.9T patent/LT2896617T/lt unknown
- 2012-11-21 HU HUE12790891A patent/HUE041592T2/hu unknown
- 2012-11-21 CR CR20210072A patent/CR20210072A/es unknown
- 2012-11-21 RS RS20210372A patent/RS61609B1/sr unknown
- 2012-11-21 ES ES12790891.1T patent/ES2694158T3/es active Active
- 2012-11-21 JP JP2014542816A patent/JP6189315B2/ja active Active
- 2012-11-22 JO JOP/2012/0351A patent/JOP20120351B1/ar active
- 2012-11-23 TW TW105136776A patent/TWI631123B/zh active
- 2012-11-23 TW TW101143843A patent/TWI597280B/zh active
- 2012-11-23 AR ARP120104425A patent/AR088983A1/es active IP Right Grant
- 2012-11-23 TW TW108113331A patent/TW201932465A/zh unknown
- 2012-11-23 UY UY0001034467A patent/UY34467A/es unknown
- 2012-11-23 TW TW107124021A patent/TWI665198B/zh active
- 2012-11-23 TW TW107115179A patent/TWI659016B/zh active
- 2012-11-26 US US13/684,670 patent/US8802847B2/en active Active
-
2014
- 2014-05-13 IL IL232585A patent/IL232585A0/en active IP Right Grant
- 2014-05-19 ZA ZA2014/03613A patent/ZA201403613B/en unknown
- 2014-05-21 CR CR20140237A patent/CR20140237A/es unknown
- 2014-05-21 CU CUP2014000055A patent/CU24257B1/es unknown
- 2014-05-21 DO DO2014000112A patent/DOP2014000112A/es unknown
- 2014-05-22 PH PH12014501160A patent/PH12014501160B1/en unknown
- 2014-05-22 EC ECIEPI20141627A patent/ECSP14001627A/es unknown
- 2014-05-22 CL CL2014001339A patent/CL2014001339A1/es unknown
- 2014-05-23 GT GT201400101A patent/GT201400101A/es unknown
- 2014-05-23 CO CO14111814A patent/CO6960555A2/es unknown
- 2014-07-01 US US14/320,875 patent/US9150573B2/en active Active
-
2015
- 2015-06-29 PH PH12015501494A patent/PH12015501494A1/en unknown
- 2015-07-10 US US14/796,703 patent/US9604948B2/en active Active
- 2015-08-18 ZA ZA2015/05970A patent/ZA201505970B/en unknown
- 2015-09-15 CU CUP2015000123A patent/CU20150123A7/es unknown
-
2016
- 2016-02-12 CL CL2016000344A patent/CL2016000344A1/es unknown
- 2016-06-16 IL IL246265A patent/IL246265B/en active IP Right Grant
- 2016-09-20 JP JP2016182821A patent/JP6340391B2/ja active Active
- 2016-11-14 HR HRP20161501TT patent/HRP20161501T1/hr unknown
-
2017
- 2017-01-16 DO DO2017000013A patent/DOP2017000013A/es unknown
- 2017-02-17 US US15/435,964 patent/US9845300B2/en active Active
- 2017-11-02 AU AU2017254916A patent/AU2017254916B2/en active Active
- 2017-11-13 JP JP2017218037A patent/JP6392436B2/ja active Active
- 2017-11-14 US US15/812,524 patent/US10364229B2/en active Active
-
2018
- 2018-08-22 JP JP2018155294A patent/JP2018199698A/ja active Pending
- 2018-11-29 IL IL263389A patent/IL263389B/en unknown
-
2019
- 2019-02-19 US US16/278,778 patent/US10633356B2/en active Active
- 2019-02-19 US US16/278,813 patent/US10633357B2/en active Active
- 2019-03-27 AU AU2019202123A patent/AU2019202123B2/en active Active
-
2021
- 2021-03-26 CY CY20211100270T patent/CY1124000T1/el unknown
- 2021-03-30 HR HRP20210507TT patent/HRP20210507T1/hr unknown
- 2021-04-05 JO JOJO/P/2021/0065A patent/JOP20210065B1/ar active
- 2021-04-05 JO JOJO/P/2021/0064A patent/JOP20210064B1/ar active
- 2021-08-25 DO DO2021000179A patent/DOP2021000179A/es unknown
-
2022
- 2022-02-24 UY UY0001039646A patent/UY39646A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
| MX390891B (es) | ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO. | |
| CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| EA201201357A1 (ru) | Антитела к cd40 | |
| EA201201016A1 (ru) | Антидоты антикоагулянтов | |
| UY34527A (es) | ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?. | |
| UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| EA201390074A1 (ru) | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения | |
| MX2012011829A (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
| UY34467A (es) | Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
| MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
| UY33207A (es) | Métodos de preparación de tiazolidinas | |
| HK1223560A1 (zh) | 人造血紅素結合組合物及其用途 | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства |